Publications by authors named "L Salinas-Ortega"
Cost analysis associated with intramuscular versus oral administration of antiretroviral therapy in the management of human immunodeficiency virus infection.
Enferm Infecc Microbiol Clin (Engl Ed)
December 2024
Objetive: To identify and analyze the resources and costs associated with the administration of intramuscular antiretroviral therapy (ART) cabotegravir+rilpivirine (CAB+RPV) compared to oral ART in the management of Human Immunodeficiency Virus Type 1 (HIV-1) infection in Spain.
Methods: An economic model was developed to identify resources and analyze costs from the perspective of the National Health System (NHS) and societal, associated with the administration of intramuscular ART (CAB+RPV) compared to oral ART over a two-year time horizon. Costs included treatment change monitoring, pharmaceutical dispensation, administration, management of adverse events to injection-site reactions (AEs-ISR), travel to the hospital, telepharmacy service, and lost work productivity.
Objective: Undiagnosed viral hepatitis is an impediment to the elimination of viral hepatitis. Clinical Practice Guidelines (CPG) recommend screening in patients with hypertransaminasemia. The aim of the study was to evaluate the early detection of viral hepatitisB andC established in our health area in this population group.
View Article and Find Full Text PDFArticle Synopsis
- The study aims to assess the economic impact of major eye diseases (glaucoma, diabetic retinopathy, diabetic macular edema, age-related macular degeneration, and high myopia) leading to vision loss and blindness in Spain over a decade (2021-2030).
- A cost analysis model was created using existing data on disease prevalence, healthcare costs, and expert validation to estimate that by 2030, around 8 million patients will incur a total cost of 99.8 billion euros, with significant contributions from direct non-healthcare costs and loss of productivity.
- Glaucoma and diabetic eye diseases are projected to have the highest financial burdens, with costs surging dramatically for diabetes-related conditions, highlighting an urgent
Purpose: The objective of the present study was to evaluate the efficiency of lorlatinib compared to alectinib and brigatinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated, in Spain.
Methods: A partitioned survival model comprised progression free, non-intracranial progression, intracranial progression, and death health states was constructed to estimate the total costs, life-years gained (LYG) and quality-adjusted life years (QALYs) accumulated in a lifetime horizon. Overall survival (OS) and progression-free survival (PFS) for lorlatinib were obtained from the CROWN study.
Objective: To determine the economic impact of the incremental consumption of resources for the diagnosis and treatment of anastomotic leak (AL) in patients after resection with anastomosis for colorectal cancer compared to patients without AL on the Spanish health system.
Method: This study included a literature review with parameters validated by experts and the development of a cost analysis model to estimate the incremental resource consumption of patients with AL versus those without. The patients were divided into three groups: 1) colon cancer (CC) with resection, anastomosis and AL; 2) rectal cancer (RC) with resection, anastomosis without protective stoma and AL; and 3) RC with resection, anastomosis with protective stoma and AL.